Clinical update The changing face of detrusor overactivity therapy in Australia
|
|
- Amos Baker
- 8 years ago
- Views:
Transcription
1 Clinical update The changing face of detrusor overactivity therapy in Australia Introduction The overactive bladder (OAB) symptom complex affects 17% of adults over age 40, and is more common in the older person, for reasons that are not fully known. Because Australia has a high standard of health care, more and more people are living longer. Therefore, the incidence and prevalence of this condition is likely to rise as our population ages. In contrast to stress incontinence, for which the cause is known and cure is readily available, the aetiology of detrusor overactivity remains unknown and cure is not yet reliably achievable. As a result, OAB will account for a relatively greater proportion of the burden of disease of female incontinence over the next decades. When managing overactive bladder, first line therapy comprises bladder retraining, but this requires an intact brain/ cerebral cortex. In the elderly, this pre-requisite may not be available. Partly because of this, and partly because bladder training is often not curative even in those with an intact cerebrum, we need a range of pharmacotherapy agents. A conundrum arises when an elderly person with OAB suffers from Alzheimer s disease and is commenced on a cholinesterase inhibitor such as donepezil hydrochloride (Aricept). In such patients, anticholinergic medications are contra-indicated, thus neuromodulation become attractive. The patient with Alzheimer s disease (or their carer) sometimes has to choose between halting the progression of the dementia, or treating the urge incontinence with anticholinergic therapy. Although this is becoming an increasingly widespread problem, this conflict was not mentioned in a very recent review of detrusor overactivity therapy in the elderly 1. In the following article, new pharmacotherapy agents are discussed, and neuromodulation options are considered. New pharmacotherapy agents Oxytrol patches were designed to deliver the widely used oral drug oxybutynin via skin absorption continuously and consistently over a 3-4 day interval. Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic M 1 / receptors resulting in relaxation of the detrusor. Oxybutynin is metabolised primarily by the cytochrome P450 enzyme systems found in the liver and gut. One of its metabolites N- desethyloxybutynin is pharmacologically active and also causes anticholinergic side effects. The transdermal administration bypasses the first pass gut and hepatic metabolism, reducing the formation of the metabolite and hence decreasing the side effects experienced. Clinical trials comparing oxybutynin patches with placebo show a comparable occurrence of dry mouth 2. Itching at the site of application is experienced by 10% to 16% of patients 3,4. The clinical efficacy of oral Oxybutynin hydrochloride (Ditropan) is similar to that of the transdermal patches 3,5. Tolterodine (Detrusitol) (dose 2mg prescribed twice daily) was developed in the 1990s, but is still not available as a PBS prescription in Australia. Although widely available on a private script, the cost (AUD$55-80) is often prohibitive. It was the first drug designed specifically to reduce the incidence of dry mouth (about 15%) 6 that is so common and debilitating in patients on KH Moore Director, The Pelvic Floor Unit, St George Hospital, University of New South Wales, Sydney Member (Co-opted) Australian and New Zealand Continence Journal Editorial Committee S Sarma Urogynaecology Fellow The Pelvic Floor Unit, St George Hospital, University of New South Wales, Sydney oral oxybutynin (about 60%). Propiverine (Detrunorm) (dose 15mg prescribed three times a day) is a non selective anticholinergic drug that also acts as a calcium channel blocker (a similar combination to the 1980s drug Terodiline that is no longer available). Dry mouth occurs in about 20% of patients but is not usually debilitating. It is widely used in the United Kingdom (UK) and is available in Europe. It is available in Australia as a private prescription on the SAS scheme. 90 Vol. 13, No. 3 Spring 2007
2 Trospium (dose 20mg prescribed twice daily) is another nonselective anticholinergic agent, but due to structural changes has only a 4% rate of dry mouth. Also, because of its structure/ metabolism it is less likely to cross the blood brain barrier and thus is less likely to cause mental confusion or other CNS side effects 7. It is widely used in the UK, available in Europe, and was recently approved in the United States of America (USA), but is not widely available in Australia. Solifenacin (Vesicare) (dose 5mg or 10 mg prescribed once daily) is the first M3 selective agent available in Australia. It was developed in the early 2000s, and after extensive clinical trials was released in Australia in late Dry mouth occurs in 8% of patients on the 5mg dose and 23% of those on the 10mg dose, but is generally not troublesome. A randomised placebo controlled trial revealed a dry rate of 50%, with significant reductions in episodes of urge incontinence, voids per day and nocturia 8. In a long-term, open label study of this patient group (and a second RCT cohort), 81% of patients completed 40 weeks of therapy, 5% of patients discontinued due to side effects 9. Whether patients with OAB should expect long term drug therapy is a separate issue, but at least this drug appeared tolerable, in contrast with six month studies of oral oxybutynin which showed a much higher dropout rate. Darifenacin (Enablex) (dose 7.5mg or 15mg prescribed once daily) Although solifenacin is the first M3 selective anticholinergic agent to become available on prescription in Australia, darifenacin was actually developed many years before. The scientific work essential to developing this drug was carried out in the late 1990s up to Two clinical trials of darifenacin were carried out in Australia in the early 2000s. However, because of commercial decisions, the makers of darifenacin merged with the manufacturers of tolterodine, and an agreement was made to focus on the marketing of tolterodine which was in a more advanced stage of clinical trials at that time. Subsequently, the company in charge of darifenacin changed (now Novartis), and presumably in view of the tremendous success of solifenacin, the makers of darifenacin have made it available as a private prescription in Australia. Neuromodulation Options Electrostimulation Traditionally, intravaginal electrostimulation is considered as a way to increase the strength of pelvic floor muscle and urethral sphincter contractions (in patients with stress incontinence). Generally, the electrostimulation is delivered at a stimulation frequency of about Hertz, to cause a tetanic muscle contraction. However, there is a substantial body of literature indicating that, at least under experimental conditions, electrical stimulation can be used to inhibit detrusor contractions. In this case, the electrical stimulation is applied to the afferent supply of the pudendal nerves, which is thought to provoke a reflex activation of sympathetic nerves to the detrusor that cause relaxation of the detrusor muscle contraction 10,11. The optimal stimulation Selecltivity (pxl ratio) Darifenacin Tolterodine Oxybutynin Propiverine Trospium 10 0 vs M 1 vs M 2 vs M 4 vs M 5 Figure 1. Muscarinic receptor subtypes Vol. 13, No. 3 Spring
3 frequency here is 5-10 Hertz, which will stimulate the nerves, but not cause a direct muscle contraction. Older studies showed that applying electrical stimulation to the dorsal penile nerve 12 or to the pudendal nerve 13, cause relaxation of the detrusor muscle. Early clinical studies of such devices in relation to women 14 showed promise. Brubaker and colleagues 15 performed a sham controlled RCT involving a take-home device that was used for 20 minutes twice daily for six weeks by 33 patients with proven detrusor overactivity (DO). After treatment, half had no further evidence of DO. However, it can be seen that the stimulation needed to be provided on a regular basis, and probably for the long term in order to maintain this benefit. Hence this therapy is not widely used for DO. Sacral nerve stimulation Based on early urologic studies of patients with partial spinal cord injuries in the 1970s and 1980s, it was realised that a nerve stimulation electrode (S3 surgical implementation device) could be permanently implanted on a chosen sacral nerve root. After an initial period of use for neurologically impaired, incontinent patients, the device was later offered to patients with refractory idiopathic detrusor overactivity (IDO). delay group), details of the other 28 participants were not given. Of those on active stimulation, 47% were dry at 6 months on a bladder diary (no pad testing performed). On cystometry 56% were stable (compared to 16% in the control group). In general terms, the likelihood of needing to surgically reposition or replace the stimulation device was 32.5%. Pain occurred at the neurostimulation site in 16% of patients, with pain at the electrode site in 19% and lead migration from the S3 nerve root in 7%. The rate of infection, or skin ulceration requiring explantation was 6%. There were no permanent adverse events or cases of nerve damage. The S3 implantable neurostimulator is available in a few centres in Australia, but at a cost of AUD$7,000 it is reserved for severe, end stage detrusor overactivity. TENS therapy Trans Cutaneous Electrical Nerve Stimulation (TENS therapy): Because implantation of a nerve stimulator at S3 was achieving promising results, the possibility that delivery of a similar current across the skin could achieve similar results was investigated. Webb and Powell 17 reported substantial benefit when they applied TENS stimulus across the S3 dermatome (peri-anally). At cystometry, in 24 patients with refractory detrusor overactivity, 45% became stable and bladder capacity at the onset of unstable contractions was improved in the remainder. Subsequently, Hasan and colleagues in gave TENS to outpatients for 3 weeks and reported significant benefit on urodynamic parameters. A randomised sham-controlled trial of TENS was then performed by Bower and colleagues in during cystometry. Figure 2. S3 surgical implantation For example, a randomised controlled trial of an S3 device implantation for nerve stimulation was offered to 155 patients with refractory IDO 16. After randomisation, the control group was put on a waiting list for 6 months and given medical therapy. At recruitment, active patients underwent a preliminary insertion of the needle electrode which was taped to their skin for three days, and activated by a temporary stimulator that was worn externally. Of the 155 enrolees, 98 had a successful test stimulation and were randomised (in a 1:2 ratio). Six months after undergoing neurosurgical implantation, outcome data was available from 76 patients (34 in active stimulation, 42 in the Figure 3. TENS machine 92 Vol. 13, No. 3 Spring 2007
4 The device was placed over the pubic bone or over the sacrum in a randomised fashion. Patients in the active group had a significant reduction in maximum detrusor pressure (p=0.008) and an increase in first desire to void (p = 0.002), with 44% of patients becoming stable, compared to 13% of those with the sham device in place (regardless of the site). Later clinical experience indicated that patients needed to use the TENS machine at least twice daily to continue benefit, so that the device is clinically cumbersome. SANS (Stoller Afferent Nerve Stimulator) therapy: Acupuncture has been helpful for detrusor overactivity, when applied to known bladder points as reported by Chang and colleagues in by increasing the levels of endogenous opioids (beta-endorphin and met-enkephalin) in the patient s cerebrospinal fluid. These substances inhibit detrusor contractions. Therefore, the idea of applying acupuncture with an electrical stimulus to the relevant acupuncture point (the medial malleolus of the ankle) was tested. In 53 patients with refractory OAB in Seattle, SANS was applied for weekly for 12 weeks 21. In the 47 patients (89%) who completed the study, there was a 25% reduction in daytime voids, and 21% reduction in nocturia, with a 35% reduction in episodes of urge incontinence. A later study of acute SANS stimulation was conducted in Paris 22. The mean volume at first detrusor contraction was increased from 163ml to 232ml, with an increase in maximum cystometric capacity from 221ml to 277ml (p < for both changes). Data regarding maximum detrusor contraction was not given. In clinical practice, the SANS device appears to have a niche role, especially for those suffering from nocturia. Magnetic field stimulation The Neotonus Chair: In early 2000s, the Neotonus chair became available. It contained a magnetic coil in the base of the chair, which produced an electric current (similar to MRI) at a frequency of 10Hz or 50Hz. Other authors showed that the 50Hz current was effective in stress incontinence for patients who were unable to contract their pelvic floor muscle 23. However, the manufacturers claimed that it was useful for mixed incontinence, but data was scant. Therefore, two separate studies were undertaken among women with a sole diagnosis of IDO 24. The first study assessed the acute effect of magnetic stimulation (provided by Neocontrol) on detrusor function during the filling phase of standard cystometry. Multiple filling cycles were performed with stimulation at Figure 4. Electromagnetic Chair a different key moment in each cycle. This was done to establish that the device could inhibit the detrusor contraction. Subsequently, a randomised sham control trial was performed to assess clinical efficacy. A total of 20 treatments, each of 20 minutes duration, were administered over six weeks with followup six weeks thereafter. Half the patients received therapy from a genuine device, the others receiving fake treatment on an identical looking/sounding sham device. The sham device contained a deflector plate to degrade the magnetic field and was located in a separate room. Outcome measures included changes in a 24-hour fluid volume chart, urine loss (24 hour pad test) and quality of life instruments. The acute chair stimulation did improve the volume at first detrusor contraction during filling, from a median value of 240ml (Interquartile range (IQR) ) to 285ml (IQR ), p = 0.03 and maximum detrusor pressure decreased from 40cm water (IQR 34 45) to 33cm water (IQR 25 41), p < The RCT was completed by 29 of 44 (66%) recruits. Of these, 15 of 29 (52%) received active treatment and 14 of 29 (48%) sham therapy. Active therapy significantly reduced the number of urge episodes per day, p < With respect to baseline, actively treated patients experienced significant reduction in voids per day and quality of life but this trend did not reach significance when compared to the sham group. Unexpected difficulty in recruitment yielded an underpowered sample size for these outcome measures, but there was no clear picture of clinical benefit. Electrical stimulator implant: Clinical trials of the surgically implantable Miniaturo device are currently ongoing in Melbourne Vol. 13, No. 3 Spring
5 and Sydney. The device differs from S3 implants in three respects. Firstly, neurosurgery is not required. Secondly, the stimulation device (a 40 mg stimulator the size of a cigarette lighter) is implanted on the inner aspect of the pubic bone. Thirdly, the stimulation electrode is implanted onto the external urethral sphincter, to provide reflex inhibitory stimuli to the detrusor muscle. The Miniaturo device is similar to the S3 implant in that a temporary stimulation lead is placed under local anaesthetic (with an external stimulator). Only patients who respond to this therapeutic trial can undergo surgical implantation of the permanent device. The cost is not yet known in Australia, but will probably be priced in thousands rather than hundreds of dollars (similar order of magnitude to S3 implant). The device was originally designed for women with severe painful bladder syndrome (interstitial cystitis). Early trial data 25 indicates marked success in this difficult group, although numbers are not sufficient for publication as yet. Because many patients with refractory urge incontinence experience their urge as painful, and because of the success of S3 implants in refractory DO, it was thought likely that this less invasive device would also have a role to play in refractory urge incontinence. Active recruitment is ongoing. Conclusion As clinicians and scientists world wide realise the growing impact of DO/OAB upon the community, greater efforts to produce new drugs and new alternative therapies are occurring. Unfortunately, because we do not yet know the cause of the OAB symptom complex, a true cure is probably some years away. References 1. Erdem N & Chu FM Management of overactive bladder and urge urinary incontinence in elderly patient. Am J Med. 2006;119: Dmochowski RR, Sand PK, Zinner NR et. al. Comparative efficacy and safety of transdermal oxybutynin and oral tolteradine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62: Dmochowski RR, Davilla W, Zinner N, Gittleman M, Saltzstein D, Lyttle S & Saunders S. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol. 2002;168: Davilla GW.Transdermal oxybutynin: a new treatment for overactive bladder. Expert Opin.Pharmacother. 2003; 4(12): Davilla GW, Daugherty CA & Saunders SW. A short-term, multicentre, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol. 2001; 166: Millard R, Tuttle J, Moore KH, Susset M, Clarke B, Dwyer P & Davis BE. Clinical efficacy and safety of Tolterodine compared to placebo in detrusor overactivity. J Urol. 1999;161: Halaska M, Ralph G, Wiedemann A, et. al. Controlled, doubleblind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20: Cardozo L, Lisec M, Millard R, Van Vierssen Trip O, Kuzmin I, Drogendijk TE, Huang M, & Ridder AM. Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent Solifenacin succinate in patients with overactive bladder. J Urol. 2004; 172: Haab F, Cardozo L, Chapple C & Ridder AM. Longterm open-label Solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005; 47: Lindstrom S & Fall M.The neurophysiological basis of bladder inhibition in response to intravaginal electrical stimulation. J Urol. 1983;129: Sundin T & Carlsson CA. Reconstruction of several dorsal roots innervating the urinary bladder. An experimental study in cats. 1. Studies on normal afferent pathways in the pelvic and pudendal nerves. Scand J Urol Nephrol. 1972; 6: Vodusek DB, Light JK & Libby J. Detrusor inhibition induced by stimulation of pudendal nerve afferents. Neurourol Urodynam. 1986; 5: Vodusek DB, Plevnik S, Vrtacnik P & Janex J. Detrusor inhibition on selective pudendal nerve stimulation in the perineum. Neurourol Urodynam. 1988; 6: Eriksen BC, Bergmann S & Mjolnerod OK. Effect of anal electrostimulation with the Incontan device in women with urinary incontence. Br J Obstet Gynaecol. 1987; 94: Brubaker L, Benson TJ, Bent A, Clark A & Short S. (1997) Transvaginal electrical stimulation for female urinary incontinence, Am J. Obstete Gynecol. 1997;177: Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna, MM, Siegel SW & Kerrebroeck PEV. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999;162: Webb RJ & Powell PH. Transcutaneous electrical nerve stimulation in patients with idiopathic detrusor instability. Neurourol & Urodynam. 1992;11: Hasan ST, Robson WA, Pridie AK & Neale DE (1994). Outcome of transcutaneous electrical stimulation in patients with detrusor instability. Neurourol & Urodynam. 1994;13: Bower WF, Moore KH & Adams RD. A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency. J Urol. 1998;106: Chang PK. Urodynamic studies in acupuncture for women with frequency, urgency and dysuria. J Urol. 1998;140: Govier FE, Litwiller S. Nitti V, Kreder KJ Jr. & Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicentre study. J Urol. 2001;165: Amarenco G, Ismael SS, Even-Schneider A, Raibaut P, D le- Wlodyka S, Parratte B & Kerdraon J (2003). Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J Urol. 2003; 169: Morris A & Moore KH. Extracorporeal magnetic stimulation. In Schussler B, Moore KH, Baessler K, Norton P & Stanton SL Textbook of Pelvic Floor Rehabilitation, In Press (Accepted August 2004). 24. Morris A, O Sullivan R, Dunkley P & Moore KH. Extracorporeal magnetic stimulation in female detrussor overactivity; simultaneous cystometry testing and randomized sham controlled trial. European Urology. In Press (Accepted 9 February 2007). 25 Erasmus MC Urology Clinische Trials: Miniaturo TM-1 for Interstitial Cystitis. URL: biocontrol.htm (Accessed 8 August 2007). 94 Vol. 13, No. 3 Spring 2007
Overactive Bladder (OAB) Content of the lecture
Overactive bladder (OAB) : Introduction and Medical Management R.J. Opsomer Cliniques St Luc, labo d urodynamique, UCL - Bruxelles Overactive Bladder (OAB) Content of the lecture The syndrome of Overactive
More informationPrimary Care management of Overactive Bladder (OAB)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Primary Care management of Overactive Bladder (OAB) Prescribing Tips All medicines for OAB have similar dose-related efficacy. More than one agent (up
More informationManagement of refractory OAB conditions
Management of refractory OAB conditions Neurotoxins and Neuromodulation Gary E. Lemack, M.D. Professor of Urology and Neurology Program Director in Urology UT-Southwestern Medical Center Overactive bladder
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report
Suffolk PCT Drug & Therapeutics Committee New Medicine Report This drug has been reviewed because it is a product that may be prescribed in primary care. Medicine Fesoterodine (Toviaz, Pfizer) Document
More informationTIBIAL NERVE STIMULATION: ONE OF SEVERAL NEW OPTIONS FOR THE MANAGEMENT OF OVERACTIVE BLADDER IN WOMEN
TIBIAL NERVE STIMULATION: ONE OF SEVERAL NEW OPTIONS FOR THE MANAGEMENT OF OVERACTIVE BLADDER IN WOMEN Scott A Farrell MD Professor Dept of Obstetrics and Gynaecology Dalhousie University Declaration of
More informationOveractive bladder is a common condition thought to. women, and is a serious condition that can lead to. significant lifestyle changes.
Overactive bladder is a common condition thought to FADE UP TO WIDE SHOT OF FEMALE MODEL WITH TRANSPARENT SKIN. URINARY BLADDER VISIBLE IN PELVIC REGION affect over 16 percent of adults. It affects men
More informationIt usually presents with a sudden urge to urinate that is very difficult to delay and may be associated with leakage. Other features include:
visited on Page 1 of 5 View this article online at http://patient.info/doctor/overactive-bladder Overactive Bladder This PatientPlus article is written for healthcare professionals so the language may
More informationNon-surgical Treatments for Urinary Incontinence. A Review of the Research for Women
Non-surgical Treatments for Urinary Incontinence A Review of the Research for Women Is This Information Right for Me? Yes, if: You are a woman who is older than 18. You are having trouble holding your
More informationGENUINE STRESS AND URGE INCONTINENCE PROTOCOL
GENUINE STRESS AND URGE INCONTINENCE PROTOCOL Using the NeuroTrac ETSTM in combination of electrostimulation and EMG Biofeedback in the treatment of female urinary incontinence. Anna Pawlaczyk Specialist
More informationUrinary Incontinence: an overview!! Neil Harris Consultant Urological Surgeon, Leeds
Urinary Incontinence: an overview!! Neil Harris Consultant Urological Surgeon, Leeds Content 1. Epidemiology of pelvic floor dysfunction Urinary incontinence Bowel dysfunction Sexual dysfunction 2. Treatment
More informationA Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
european urology 54 (2008) 740 764 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology A Systematic Review and Meta-Analysis of Randomized Controlled Trials
More information1/07/2014 HOW COMMON? FEMALE URINARY INCONTINENCE: OVERACTIVE BLADDER NORMAL BLADDER FUNCTION CAUSES OF URINARY INCONTINENCE HISTORY RISK FACTORS
HOW COMMON? FEMALE URINARY INCONTINENCE: OVERACTIVE BLADDER Judith Goh AO MBBS(Qld) FRANZCOG CU PhD Urogynaecologist Griffith University Greenslopes Private Hospital, Brisbane Pindara Private Hospital,
More informationPosterior Tibial Nerve Stimulation for Voiding Dysfunction. Original Policy Date
MP 7.01.86 Posterior Tibial Nerve Stimulation for Voiding Dysfunction Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
More informationOVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS:
2014 OVERACTIVE BLADDER DIAGNOSIS AND TREATMENT OF OVERACTIVE BLADDER IN ADULTS: AUA/SUFU Guideline (2012); Amended (2014) For Primary Care Providers OVERACTIVE BLADDER Diagnosis and Treatment of Overactive
More informationComparison of Fesoterodine, Tolterodine, Oxybutynin and Solifenacin in patients with overactive bladder A systematic review
Comparison of Fesoterodine, Tolterodine, Oxybutynin and Solifenacin in patients with overactive bladder A systematic review Hamed Kakarª, Bastiaantje M. Kok b, Sahar Mokhles c, Malalay Sarwar d * Supervisors:
More informationTreatments for Overactive Bladder
Treatments for Overactive Bladder Patient Information Author ID: SA Leaflet Number: Gyn 051 Name of Leaflet: Treatments for overactive bladder Date Produced: October 2014 Review Date: October 2016 Treatment
More informationUrinary Incontinence (Involuntary Loss of Urine) A Patient Guide
Urinary Incontinence (Involuntary Loss of Urine) A Patient Guide Urinary Incontinence (Urine Loss) This booklet is intended to give you some facts on urinary incontinence - what it is, and is not, and
More informationFemale Urinary Incontinence
Female Urinary Incontinence Molly Heublein, MD Assistant Professor Clinical Medicine UCSF Women s Health Primary Care Disclosures I have nothing to disclose. 1 Objectives Review the problem Feel confident
More informationPharmacological management of overactive bladder syndrome
Pharmacological management of overactive bladder syndrome Bardsley, A. Postprint deposited in Curve January 2016 Original citation: Bardsley, A. (2014) Pharmacological management of overactive bladder
More informationOveractive Bladder Syndrome (OAB): Guidelines for prescribing. (CLINICAL GUIDELINE NO.)
Overactive Bladder Syndrome (OAB): Guidelines for prescribing. (CLINICAL GUIDELINE NO.) Document Reference Number: Ratified By: Ratified: (s) Reviewed: Next Review : Responsibility for Review: Contributors:
More informationA review of antimuscarinic prescribing for urinary incontinence in primary care
A review of antimuscarinic prescribing for urinary incontinence in primary care Seema Gadhia On behalf of NHS Buckinghamshire Medicines Management Team In Collaboration with Introduction Urinary incontinence
More informationPrimary Care Management Guidelines Female Urinary Incontinence. Overview of Lecture
Primary Care Management Guidelines Female Urinary Incontinence Professor Don Wilson Department of Women s and Children s Health Dunedin School of Medicine University of Otago GP Teaching for Roy Morris,
More informationApril 12, 2013 Mandy C. Leonard, Pharm.D., BCPS Department of Pharmacy
April 12, 2013 Mandy C. Leonard, Pharm.D., BCPS Department of Pharmacy Describe when medications are used for urinary incontinence (UI) Review medications used in UI including mechanism of action, key
More informationFemale Urinary Incontinence
Female Urinary Incontinence Molly Heublein, MD Assistant Professor Clinical Medicine UCSF Women s Health Primary Care Disclosures I have nothing to disclose. Objectives Which is most true? Review the problem
More informationNormal bladder function requires a coordinated effort between the brain, spinal cord, and the bladder.
.. Urinary Incontinence Urinary incontinence is not an inevitable part of aging, and it is not a disease. The loss of bladder control - called urinary incontinence - affects between 13 and 17 million adult
More informationURINARY INCONTINENCE
URINARY INCONTINENCE What is urinary incontinence? Urinary incontinence is the uncontrollable loss of urine. The amount of urine leaked can vary from only a few drops when you cough or sneeze to entirely
More informationThe role of neuromodulation in the management of urinary urge incontinence
Original Article NEUROMODULATION FOR MANAGING URINARY URGE INCONTINENCE P. ABRAMS et al. Neuromodulation is increasingly becoming an important part of the treatment strategy for bladder dysfunction. In
More informationOveractive bladder syndrome (OAB)
Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or desire to pass
More informationShort- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence
Original Article SOLIFENACIN AND MIXED URINARY INCONTINENCE STASKIN and TE Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence DAVID R. STASKIN
More informationSaint Mary s Hospital. Gynaecology Service Warrell Unit. Overactive Bladder. Information for Patients
Saint Mary s Hospital Gynaecology Service Warrell Unit Overactive Bladder Information for Patients What is Overactive Bladder (OAB)? OAB is a condition that causes you to need to pass urine more often
More informationOAB (Overactive Bladder)
OAB (Overactive Bladder) PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This webcast has been supported by an educational grant
More informationPrescribing Pathway for Drug Treatment for Overactive Bladder.
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG - Prescribing Clinical Network
More informationLondon New Drugs Group APC/DTC Briefing Document Mirabegron (Betmiga TM ) for overactive bladder March 2013
London New Drugs Group APC/DTC Briefing Document Mirabegron (Betmiga TM ) for overactive bladder March 2013 Summary Mirabegron is first of a new class of drug, beta-3-adrenoceptor agonists, for the treatment
More informationCase Study on the use of Electro acupuncture for Overactive Bladder. Siu Cheetham Physiotherapist Kwong Wah Hospital
Case Study on the use of Electro acupuncture for Overactive Bladder Siu Cheetham Physiotherapist Kwong Wah Hospital Overactive bladder Approximately 34 million adults in the United States The International
More informationUrinary Continence. Second edition FAST FACTS. by Julian Shah and Gary Leach. Anatomy and physiology 7. Investigations and diagnosis 11
FAST FACTS Urinary Continence Second edition Indispensable Guides to by Julian Shah and Gary Leach Clinical Practice Anatomy and physiology 7 Investigations and diagnosis 11 Detrusor instability 28 Primary
More informationMixed urinary incontinence - sling or not sling
Mixed urinary incontinence - sling or not sling 吳 銘 斌 Ming-Ping Wu, M.D.,Ph.D. Director, Div. Urogynecology & Pelvic Floor Reconstruction, Chi Mei Foundation Hospital, Tainan, Taiwan Assistant Professor,
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Posterior Tibial Nerve Stimulation for Voiding Dysfunction NMP368 Effective Date*: September 2007 Updated: October 2015 This National Medical Policy is subject
More informationProspective Study of Transcutaneous Parasacral Electrical Stimulation for Overactive Bladder in Children: Long-Term Results
Prospective Study of Transcutaneous Parasacral Electrical Stimulation for Overactive Bladder in Children: Long-Term Results Patrícia Lordêlo, Paulo Vitor Lima Soares, Iza MacIel, Antonio Macedo, Jr. and
More informationOveractive bladder (OAB) is a
Menopause Matters from Diagnosis and Treatment of Overactive Bladder in Midlife Women www.menopause.org Tyler M. Muffly, MD; Marie Fidela R. Paraiso, MD Overactive bladder is a debilitating health condition
More informationSacral Nerve Neuromodulation/Stimulation
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Sacral Nerve Neuromodulation/Stimulation Number 7.01.69 Effective
More informationClinical Commissioning Policy: Sacral Nerve Stimulation for Overactive Bladder
Clinical Commissioning Policy: Sacral Nerve Stimulation for Overactive Bladder Reference: NHS England XXX/X/X 1 Clinical Commissioning Policy: Sacral Nerve Stimulation for Overactive Bladder Prepared by
More informationOveractive Bladder (OAB)
Overactive Bladder (OAB) Overactive bladder is a problem with bladder storage function that causes a sudden urge to urinate. The urge may be difficult to suppress, and overactive bladder can lead to the
More informationbotulinum toxin type A 50, 100, 200 Allergan units/vial (Botox ) SMC No. (916/13) Allergan Ltd
botulinum toxin type A 50, 100, 200 Allergan units/vial (Botox ) SMC No. (916/13) Allergan Ltd 06 September 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationMEDICAL COVERAGE POLICY SERVICE: Urinary Incontinence Treatments
Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit
More informationmirabegron 25mg and 50mg prolonged-release tablets (Betmiga ) SMC No. (862/13) Astellas Pharma Ltd
mirabegron 25mg and 50mg prolonged-release tablets (Betmiga ) SMC No. (862/13) Astellas Pharma Ltd 05 April 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationClassification of Mixed Incontinence
european urology supplements 5 (2006) 837 841 available at www.sciencedirect.com journal homepage: www.europeanurology.com Classification of Mixed Incontinence Christopher Chapple * Sheffield Hallam University,
More informationUrinary incontinence and Prolapse. Dr Zeelha Abdool Consultant OBGYN Steve Biko Academic Hospital
Urinary incontinence and Prolapse Dr Zeelha Abdool Consultant OBGYN Steve Biko Academic Hospital Definitions: IUGA/ICS standardized terminology Urinary incontinence (symptom): complaint of involuntary
More informationDarifenacin: first M3 receptor antagonist for overactive bladder Steve Chaplin MSc, MRPharmS and Christopher Chapple BSc, MD, FRCS(Urol)
Darifenacin: first M3 receptor antagonist for overactive bladder Steve Chaplin MSc, MRPharmS and Christopher Chapple BSc, MD, FRCS(Urol) PRODUCT PROFILE Proprietary name: Emselex Constituents: darifenacin
More informationUrinary Incontinence FAQ Sheet
Urinary Incontinence FAQ Sheet Are you reluctant to talk to your doctor about your bladder control problem? Don t be. There is help. Loss of bladder control is called urinary incontinence. It can happen
More informationGwen Griffith Clinical Nurse Specialist Bolton NHS foundation Trust
Gwen Griffith Clinical Nurse Specialist Bolton NHS foundation Trust Overview Setting the Scene Beginning of the journey & specialist nurse role Why people with MS experience bladder problems MS and the
More informationDiagnosis and treatment of overactive bladder in menopausal women
Diagnosis and treatment of overactive bladder in menopausal women Tyler M. MUFFLY, MD a, Fellow Marie Fidela R. PARAISO, MD a, Professor From the a Center of Urogynecology and Pelvic Floor Disorders, Obstetrics,
More informationUrinary Incontinence in Women. Susan Hingle, M.D. Department of Medicine
Urinary Incontinence in Women Susan Hingle, M.D. Department of Medicine Background Estimated 13 million Americans with urinary incontinence Women are affected twice as frequently as men Only 25% will seek
More informationWomen suffer in silence
Women suffer in silence Stress urinary incontinence is the involuntary loss of urine resulting from increased intra-abdominal pressure. In people who suffer with this condition, forms of exertion such
More informationMultiple sclerosis information
Multiple sclerosis information for health and social care professionals MS: an overview Diagnosis Types of MS Prognosis Clinical measures A multidisciplinary approach to MS care Self-management Relapse
More informationQuestion ID: 6 Question type: Intervention Question: Does treatment of overactive bladder symptoms prevent falls in the elderly?
PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation projects. QUESTION
More informationOveractive bladder and urgency incontinence
Overactive bladder and urgency incontinence As a health care provider you can make a significant difference to the quality of life of patients like these by addressing urinary incontinence, introducing
More informationThe Efficacy of the Antimuscarinic Drug Oxybutynin in the Treatment Women with Overactive Bladder (OAB) Symptoms
THE OVERACTIVE IRAQI POSTGRADUATE BLADDER MEDICAL JOURNAL The Efficacy of the Antimuscarinic Drug Oxybutynin in the Treatment Women with Overactive Bladder (OAB) Symptoms Jassim Mohammad Alkhazraji*, Ban
More informationNeuromodulation for the Treatment of Refractory Interstitial Cystitis Kenneth M. Peters, MD
CLINICAL MANAGEMENT OF INTERSTITIAL CYSTITIS Neuromodulation for the Treatment of Refractory Interstitial Cystitis Kenneth M. Peters, MD Department of Urology, William Beaumont Hospital, Royal Oak, MI
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 18 December 2002 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationYour Comprehensive Guide to Overactive Bladder
Your Comprehensive Guide to Overactive Bladder Learn more about OAB in the Powder Room www.powderroom.ca Table of Contents Learning about overactive bladder (OAB) 1 What is overactive bladder (OAB)? 2
More informationCase Based Urology Learning Program
Case Based Urology Learning Program Resident s Corner: UROLOGY Case Number 21 CBULP 2011 068 Case Based Urology Learning Program Editor: Associate Editors: Manager: Case Contributors: Steven C. Campbell,
More informationBowel and Bladder Dysfunction in MS. Tracy Walker, WOCN, MSCN, FNP C Nurse Practitioner MS Institute at Shepherd Center. Bladder Dysfunction
Bowel and Bladder Dysfunction in MS Tracy Walker, WOCN, MSCN, FNP C Nurse Practitioner MS Institute at Shepherd Center Bladder Dysfunction Approximately 75% of people with MS experience bladder problems
More informationManaging Overactive Bladder in Primary care
Dudley Robinson * MD FRCOG Linda Cardozo 2* MD FRCOG Consultant Urogynaecologist 2 Professor of Urogynaecology * Department of Urogynaecology, Kings College Hospital, London Correspondence: Dudley Robinson
More informationTopic review: Clinical presentation and diagnosis of urinary incontinence in the elderly. Prapa Pattrapornpisut 7 June 2012
1 Topic review: Clinical presentation and diagnosis of urinary incontinence in the elderly Prapa Pattrapornpisut 7 June 2012 2 Urinary incontinence Definition the complaint of any involuntary leakage of
More informationUrinary incontinence. The management of urinary incontinence in women. Issued: September 2013 last modified: January 2015. NICE clinical guideline 171
Urinary incontinence The management of urinary incontinence in women Issued: September 2013 last modified: January 2015 NICE clinical guideline 171 guidance.nice.org.uk/cg171 NICE has accredited the process
More informationSOGC Recommendations for Urinary Incontinence
The quality of evidence is rated, and recommendations are made using the criteria described by the Canadian Task Force on Preventive Health Care. Clinical Practice Guidelines: The Evaluation of Stress
More informationCorporate Medical Policy
Corporate Medical Policy Pelvic Floor Stimulation as a Treatment of Urinary and Fecal File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pelvic_floor_stimulation_as_a_treatment_of_urinary_and_fecal_incontinence
More informationLincolnshire Knowledge and Resource Service
Lincolnshire Knowledge and Resource Service This search summary contains the results of a literature search undertaken by the Lincolnshire Knowledge and Resource Service librarians in; January 2012 All
More informationThe Bathroom has been central in our lives through the ages. Bladder Control Problems. Bladder Control Problems. A Common Problem:
When You Gotta Go. Understanding and Conquering Urinary Incontinence and the Overactive Bladder Syndrome Richard T. Kershen M.D. Assistant Professor UVM Department of Surgery, Division of Urology Director,
More informationNeuroStar TMS Therapy Patient Guide for Treating Depression
NeuroStar TMS Therapy Patient Guide for Treating Depression This NeuroStar TMS Therapy Patient Guide for Treating Depression provides important safety and use information for you to consider about treating
More informationMEDICAL COVERAGE POLICY SERVICE: Urinary Incontinence Treatments
Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit
More informationThe overactive bladder and bladder retraining
Oxford University Hospitals NHS Trust The overactive bladder and bladder retraining Information for patients Normal bladder function Your bladder normally stores urine produced by your kidneys. The kidneys
More informationPercutaneous Tibial Nerve Stimulation for the Long-Term Treatment of Overactive Bladder: 3-Year Results of the STEP Study
Percutaneous Tibial Nerve Stimulation for the Long-Term Treatment of Overactive Bladder: 3-Year Results of the STEP Study Kenneth M. Peters,*, Donna J. Carrico, Leslie S. Wooldridge, Christopher J. Miller
More informationLifestyle changes. Pelvic floor muscle training
Incontinence, urinary - Treatment Treating urinary incontinence The treatment you receive for urinary incontinence will depend on the type of incontinence you have and the severity of your symptoms. If
More informationPROCEDURE FOR THE ASSESSMENT OF ADULTS AND CHILDREN WITH BLADDER OR BOWEL DYSFUNCTION
PROCEDURE FOR THE ASSESSMENT OF ADULTS AND CHILDREN WITH BLADDER OR BOWEL DYSFUNCTION First Issued Issue Version One Purpose of Issue/Description of Change Planned Review Date Procedure for the effective
More informationKELLI DEWITT WHITEHEAD, RN, MS, ARNP
CIRRICULUM VITAE KELLI DEWITT WHITEHEAD, RN, MS, ARNP Associated Urologist, PA 341 Wheatfield, Suite 180 Sunnyvale, TX 75182 972-270-8859 EDUCATION Master of Science, Family Nurse Practitioner University
More information1 ST JAMAICAN PAEDIATRIC NEPHROLOGY CONFERENCE
in association with 1 ST JAMAICAN PAEDIATRIC NEPHROLOGY CONFERENCE Jamaica Conference Centre Kingston, Jamaica October 4 th 2014 VOIDING DISORDERS IN CHILDREN Dr. Colin Abel Paediatric Urologist Bustamante
More informationTHE MANAGEMENT OF URINARY INCONTINENCE WITHIN A STROKE UNIT POPULATION REENA DHAMI STROKE CNS EPSOM & ST.HELIER UNIVERSITY HOSPITALS
THE MANAGEMENT OF URINARY INCONTINENCE WITHIN A STROKE UNIT POPULATION REENA DHAMI STROKE CNS EPSOM & ST.HELIER UNIVERSITY HOSPITALS Definition Urinary Incontinence is AN INABILITY TO HOLD URINE until
More informationTHE ROLE OF OVERACTIVE BLADDER TREATMENT
THE ROLE OF OVERACTIVE BLADDER TREATMENT Prof. Junizaf, SpOG(K) Division of Urogynecology Department of Obstetrics and Gynecology School of Medicine, University of Indonesia/ Dr. Cipto Mangunkusumo Hospital
More informationMedication for Overactive Bladder
Saint Mary s Hospital Gynaecology Service Warrell Unit Medication for Overactive Bladder Information for Patients What medication is available for overactive bladder? There are two types of medication
More informationUrinary incontinence during sexual intercourse: a common, but rarely volunteered, symptom
British Journal of Obstetrics and Gynaecology April 1988, Vol. 95, pp. 77-81 Urinary incontinence during sexual intercourse: a common, but rarely volunteered, symptom PAUL HILTON Summary. A total of 4
More informationIncontinence. What is incontinence?
Incontinence What is incontinence? Broadly speaking, the medical term incontinence refers to any involuntary release of bodily fluids, but many people associate it strongly with the inability to control
More informationPainful Bladder Syndrome and Interstitial Cystitis
Painful Bladder Syndrome and Interstitial Cystitis PAINFUL BLADDER AND INTERSTITIAL CYSTITIS OVERVIEW Painful bladder syndrome/interstitial cystitis (PBS/IC) is a disorder with symptoms of mild to severe
More informationPROCEEDINGS INCIDENCE AND PREVALENCE OF STRESS URINARY INCONTINENCE * Ananias C. Diokno, MD ABSTRACT
INCIDENCE AND PREVALENCE OF STRESS URINARY INCONTINENCE * Ananias C. Diokno, MD ABSTRACT Urinary incontinence is a worldwide problem that affects millions of women, although the magnitude of the problem
More informationFemale Urinary Disorders and Pelvic Organ Prolapse
Female Urinary Disorders and Pelvic Organ Prolapse Richard S. Bercik, M.D. Director, Division of Urogynecology & Reconstruction Pelvic Surgery Department of Obstetrics, Gynecology & Reproductive Sciences
More informationManaging Overactive Bladder
Patient Educational Material Managing Overactive Bladder The bladder s job is pretty simple: hold urine until full, then empty when we get to a restroom. When you have an overactive bladder, the bladder
More informationBJUI. A review of adherence to drug therapy in patients with overactive bladder
2008 BJU International. No claim to original US government works Mini-review Article ADHERENCE TO DRUG THERAPY IN PATIENTS WITH OAB BASRA et al. BJUI BJU INTERNATIONAL A review of adherence to drug therapy
More informationCase Study Activity: Managing Overactive Bladder in the Community Pharmacy Answers to Interactive Questions and Resources
Case Study Activity: Managing Overactive Bladder in the Community Pharmacy Answers to Interactive Questions and Resources Case 3: Updates on Overactive Bladder Treatments Activity Preview Overactive bladder
More informationDr Eva Fong. Urologist Auckland
Dr Eva Fong Urologist Auckland Urinary incontinence: Treatment options GPCME 2013 Eva Fong Urologist Urinary incontinence Is not normal part of aging or childbearing We can make it better Urinary incontinence:
More informationEvaluating Prescription Drugs Used to Treat: Overactive Bladder. Comparing Effectiveness, Safety, and Price
Evaluating Prescription Drugs Used to Treat: Overactive Bladder Comparing Effectiveness, Safety, and Price Our Recommendations The six prescription drugs used to treat the urination disorder, overactive
More informationNocturia. Dudley Robinson MD FRCOG Department of Urogynaecology, Kings College Hospital, London, UK
Nocturia Dudley Robinson MD FRCOG Department of Urogynaecology, Kings College Hospital, London, UK Nocturia: Definition The complaint of interruption of sleep one or more times because of the need to
More informationPOCKETGUIDE. Overactive bladder. Written by Natalia Price and Simon Jackson. Reviewed by Sally Hope, Michael Kirby and Adrian Wagg.
POCKETGUIDE Overactive bladder Written by Natalia Price and Simon Jackson Reviewed by Sally Hope, Michael Kirby and Adrian Wagg Funded by Relax, Urgency controlled Please consult Summary of Product Characteristics
More informationsymptoms of Incontinence
Types, causes and symptoms of Urinary Incontinence Aims and Objectives Aim: To have an understanding of the types and causes of urinary incontinence. Objectives: To be aware of the incidence and prevalence
More informationThe Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis
european urology 54 (2008) 543 562 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Neuro-urology The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update
More informationImproving access and reducing costs of care for overactive bladder through a multidisciplinary delivery model
Improving access and reducing costs of care for overactive bladder through a multidisciplinary delivery model Trafford Crump, Ph.D. Department of Surgery, University of Calgary Presentation to: Canadian
More informationSpinal Cord Stimulation (SCS) Therapy: Fact Sheet
Spinal Cord Stimulation (SCS) Therapy: Fact Sheet What is SCS Therapy? Spinal cord stimulation (SCS) may be a life-changing 1 surgical option for patients to control their chronic neuropathic pain and
More informationAdult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline
Adult Urodynamics: American Urological Association (AUA)/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Guideline RECOMMENDATIONS 1 Conditional: Clinicians who are making
More informationManagement of Neurogenic Bladder Disorders
Management of Neurogenic Bladder Disorders Andrea Staack, MD, PhD Pelvic Reconstructive Surgery, Urinary Incontinence & Female Urology Department of Urology Loma Linda University, CA What will you learn
More informationTreatments for Urinary Incontinence in Women
Treatments for Urinary Incontinence in Women National Kidney and Urologic Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH
More information